The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Mergers & AcquisitionsMedium•1 May 2026•

1 min read

Gilead Sciences Completes Acquisition of Arcellx for $115 Per Share

Key Facts

1Gilead Sciences completed its acquisition of Arcellx for $115 per share in cash plus a $5 contingent value right.

2Arcellx was merged as a wholly owned subsidiary of Gilead effective April 28, 2026.

Gilead Sciences has finalized its acquisition of Arcellx, completing the transaction at a price of $115 per share in cash. The deal also includes a contingent value right (CVR) worth an additional $5 per share, tied to the achievement of specific future milestones. Effective April 28, 2026, Arcellx has been integrated as a wholly owned subsidiary of Gilead. This merger will result in the delisting of ACLX shares from public exchanges and a significant shift in beneficial ownership. The acquisition underscores Gilead's strategic focus on expanding its footprint within the biotechnology sector through high-value M&A activity. Market analysts are closely watching how this integration will bolster Gilead's therapeutic pipeline and long-term earnings potential.